Dermata Therapeutics Inc (DRMA)

$6.29 -0.23 (-3.52%)
Market Cap 4.46M
Revenue (ttm) 0.00
Net Income (ttm) -12.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 18,492
Avg Vol 16,047
Day's Range N/A - N/A
Shares Out 638,000.00
Stochastic %K 67%
Beta 0.56
Analysts Strong Sell
Price Target $30.00

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 800 2543
Address:
3525 Del Mar Heights Rd., Suite 332, San Diego, United States
Iiii1ii
Iiii1ii Aug. 6 at 10:58 PM
$DRMA
0 · Reply
PTST
PTST Aug. 6 at 11:59 AM
$DRMA is this ready
0 · Reply
Iiii1ii
Iiii1ii Aug. 5 at 11:48 PM
$DRMA Squeeze imminent
0 · Reply
Olg59
Olg59 Aug. 5 at 12:11 PM
$DRMA Waiting for a drop under 5 to add
0 · Reply
LegendaryCharts
LegendaryCharts Aug. 5 at 1:34 AM
$DRMA news due
0 · Reply
Bubbasoup09
Bubbasoup09 Aug. 5 at 12:14 AM
$DRMA can y’all drop it alittle so I can get some freaking bids filled?? Jeez, Skirting my bids all day!
0 · Reply
Iiii1ii
Iiii1ii Aug. 4 at 10:58 PM
$DRMA On the verge of explosion
0 · Reply
Iiii1ii
Iiii1ii Aug. 4 at 7:02 PM
$DRMA Give me $20 of love
1 · Reply
AlwaysLearning72
AlwaysLearning72 Aug. 4 at 7:00 PM
$DRMA looking strong
0 · Reply
makedatbread88
makedatbread88 Aug. 4 at 6:19 PM
$COEP $DRMA $NAAS $OLB $VERB This post aged well. VERB went huge who’s next?!
1 · Reply
Latest News on DRMA
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jul 8, 2025, 8:00 AM EDT - 4 weeks ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 9:00 AM EDT - 3 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Apr 15, 2025, 8:30 AM EDT - 4 months ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 8:15 PM EDT - 4 months ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 10:21 AM EDT - 4 months ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 9:57 AM EDT - 4 months ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 27, 2025, 8:00 AM EDT - 4 months ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 17, 2025, 4:16 PM EDT - 5 months ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Mar 4, 2025, 8:03 AM EST - 5 months ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Feb 25, 2025, 7:58 AM EST - 5 months ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata to Present on BioPub on January 31, 2025

Jan 29, 2025, 4:05 PM EST - 6 months ago

Dermata to Present on BioPub on January 31, 2025

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 28, 2025, 4:05 PM EST - 6 months ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 23, 2025, 4:15 PM EST - 6 months ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 7 months ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Jan 21, 2025, 8:00 AM EST - 7 months ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 16, 2024, 9:00 AM EST - 8 months ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 10, 2024, 9:00 AM EST - 8 months ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 3, 2024, 9:00 AM EST - 8 months ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:15 PM EST - 9 months ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Nov 11, 2024, 8:35 AM EST - 9 months ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Oct 8, 2024, 4:15 PM EDT - 10 months ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 17, 2024, 5:15 PM EDT - 11 months ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 11 months ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Sep 5, 2024, 4:05 PM EDT - 11 months ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 17, 2024, 8:30 AM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 27, 2024, 4:05 PM EDT - 1 year ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Feb 1, 2024, 9:00 AM EST - 1 year ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Jan 4, 2024, 4:05 PM EST - 1 year ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 20, 2023, 4:05 PM EST - 1 year ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 1:30 PM EST - 1 year ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 16, 2023, 8:00 AM EST - 1 year ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Oct 26, 2023, 9:00 AM EDT - 1 year ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Jun 27, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 13, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

Jun 8, 2023, 9:00 AM EDT - 2 years ago

Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 26, 2023, 4:00 PM EDT - 2 years ago

Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

May 24, 2023, 8:00 AM EDT - 2 years ago

Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023, 4:05 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package

Apr 20, 2023, 6:00 AM EDT - 2 years ago

Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package

Dermata Therapeutics Announces Closing of $5.0 Million Public Offering

Mar 20, 2023, 4:30 PM EDT - 2 years ago

Dermata Therapeutics Announces Closing of $5.0 Million Public Offering

Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering

Mar 16, 2023, 1:15 PM EDT - 2 years ago

Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

Feb 21, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

Dec 5, 2022, 8:30 AM EST - 2 years ago

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

Iiii1ii
Iiii1ii Aug. 6 at 10:58 PM
$DRMA
0 · Reply
PTST
PTST Aug. 6 at 11:59 AM
$DRMA is this ready
0 · Reply
Iiii1ii
Iiii1ii Aug. 5 at 11:48 PM
$DRMA Squeeze imminent
0 · Reply
Olg59
Olg59 Aug. 5 at 12:11 PM
$DRMA Waiting for a drop under 5 to add
0 · Reply
LegendaryCharts
LegendaryCharts Aug. 5 at 1:34 AM
$DRMA news due
0 · Reply
Bubbasoup09
Bubbasoup09 Aug. 5 at 12:14 AM
$DRMA can y’all drop it alittle so I can get some freaking bids filled?? Jeez, Skirting my bids all day!
0 · Reply
Iiii1ii
Iiii1ii Aug. 4 at 10:58 PM
$DRMA On the verge of explosion
0 · Reply
Iiii1ii
Iiii1ii Aug. 4 at 7:02 PM
$DRMA Give me $20 of love
1 · Reply
AlwaysLearning72
AlwaysLearning72 Aug. 4 at 7:00 PM
$DRMA looking strong
0 · Reply
makedatbread88
makedatbread88 Aug. 4 at 6:19 PM
$COEP $DRMA $NAAS $OLB $VERB This post aged well. VERB went huge who’s next?!
1 · Reply
Iiii1ii
Iiii1ii Aug. 4 at 2:47 PM
$DRMA 💎
0 · Reply
Iiii1ii
Iiii1ii Aug. 4 at 2:20 PM
$DRMA $20+ this week?
0 · Reply
SqueezeMorpheus
SqueezeMorpheus Aug. 4 at 9:33 AM
$DRMA $DRUG $DNA $TNXP ,
0 · Reply
BioTechHealthX
BioTechHealthX Aug. 4 at 2:51 AM
$DRMA Dermata is making waves with its late-stage acne treatment and strategic NASDAQ compliance moves. Learn more about DRMA stock here. https://biotechhealthx.com/biotech-news/drma-stock-alert-why-dermata-therapeutics-drma-could-be-the-hidden-biotech-gem-of-2025/
0 · Reply
jdlman
jdlman Aug. 1 at 11:23 PM
$DRMA
0 · Reply
Iiii1ii
Iiii1ii Aug. 1 at 8:31 PM
$DRMA
0 · Reply
stockanalysis_
stockanalysis_ Aug. 1 at 8:15 PM
After Hours Gainers: $AACG $PBM $OTRK $EZGO $DRMA View the entire list here: https://stockanalysis.com/markets/afterhours/?ref=saveontrading
0 · Reply
makedatbread88
makedatbread88 Aug. 1 at 8:04 PM
The markets are getting ugly and a pullback has been necessary. Market was way too overbought. In poor conditions, traders target low float stocks My FAVORITE low float stocks for 50-200% plus moves are $NAAS $DRMA $OLB $VERB and $COEP . At least one goes big within 30 days my prediction. Which one goes first?! 🐎🚀
3 · Reply
TwongStocks
TwongStocks Aug. 1 at 8:03 PM
Today's reverse split results: $DRMA 1 for 10 Previous close $0.623199, $6.23199 split-adjusted Today's close $6.45 🟢Up 3.5% $HCTI 1 for 249. Previous close $0.0312, $7.7688 split-adjusted Today's close $4.75 🔴Down 38.86%
0 · Reply
RedHottie
RedHottie Aug. 1 at 5:49 PM
$HCTI Soooo…. $DRMA also split this morning and close to the same price as us roughly $1 less, but we’re 45% lower than them. $DRMA come grab our cheap shares and we will buy yours as well if we ever make any money 🤗🤗
0 · Reply
DonZulu
DonZulu Aug. 1 at 4:21 PM
$DRMA we need some news soon. I have a 1$ avg looking for 3$ pre split
0 · Reply
Iiii1ii
Iiii1ii Aug. 1 at 4:12 PM
$DRMA 1000%?
0 · Reply